<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345615</url>
  </required_header>
  <id_info>
    <org_study_id>H17-01060</org_study_id>
    <nct_id>NCT03345615</nct_id>
  </id_info>
  <brief_title>Standard Versus Intensive Monitoring After Myocardial Infarction Looking for Atrial Fibrillation</brief_title>
  <acronym>SIMPL-AF</acronym>
  <official_title>Standard Versus Intensive Monitoring After Myocardial Infarction Looking for Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After a myocardial infarction (MI), patients discharged home in sinus rhythm may develop AF
      that is asymptomatic, undetected, and undertreated. Previous studies (CARISMA and ARREST)
      have demonstrate high rates of new-onset AF recorded on implantable loop recorder (ILR),
      although the routine implantation of ILRs post-MI remains costly and invasive. The external
      loop recorder may effectively identify patients with new-onset AF through a validated
      diagnostic algorithm and targeted monitoring during a high-risk period (immediately after
      hospital discharge). We will prospectively randomize patients to receive an external loop
      recorder or standard care, evaluating rates of new-onset AF developing within 30 days after
      MI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SIMPL-AF trial will evaluate the role of intensive monitoring after myocardial
      infarction, assessing for new-onset AF after hospital discharge. Patients will be randomized
      to receive intensive monitoring or standard care in a 2:1 distribution. Patients randomized
      to intensive monitoring will receive a SpiderFlash® monitor, worn for 30-days after discharge
      and returned for analysis.

      The primary objective of this study is to evaluate at the incidence of new-onset AF at
      30-days post-MI using an intensive monitoring strategy, compared to standard of care.
      Secondary objectives include the impact of intensive monitoring on oral anticoagulation rates
      at 90-days and 1-year after monitoring, and the risk factors for developing new-onset AF, and
      the variables associated with initiating or withholding anticoagulation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:1 enrollment into parallel groups (intensive monitoring vs. standard care).</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of new-onset AF at 30-days post-MI</measure>
    <time_frame>30 days</time_frame>
    <description>New-onset AF detected through intensive monitoring or standard care (routine assessment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of oral anticoagulation</measure>
    <time_frame>90 days and 1-year</time_frame>
    <description>Prescription of anticoagulation after intensive monitoring or standard care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF-related hospitalization</measure>
    <time_frame>90 days and 1-year</time_frame>
    <description>Rates of AF-related hospitalization after intensive monitoring or standard care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite cardiovascular and hospitalization events</measure>
    <time_frame>90 days and 1-year</time_frame>
    <description>All-cause hospitalization, re-infarction, stroke, and death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Atrial Fibrillation New Onset</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Intensive Monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30-day ambulatory cardiac event monitoir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard Care (no supplemental monitoring)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>30-day ambulatory cardiac event monitor</intervention_name>
    <description>SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.</description>
    <arm_group_label>Intensive Monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ST-elevation myocardial infarction (STEMI) or Non-ST-elevation
             myocardial infarction (NSTEMI; Third Universal Definition of MI) with or without PCI.
             All patients must have troponin elevation.

          -  No history of AF during hospitalization, at discharge, or pre-existing AF documented
             on history (i.e. hospital records, previous hospitalization, ECG records).

          -  No anticoagulation for AF or other indications (i.e. LV thrombus, heart valves, venous
             thromboembolism/deep venous thrombosis).

          -  No concomitant disease expected to reduce expected lifespan to &lt;2 yrs.

        Exclusion Criteria:

          -  Patients receiving CABG surgery during this hospitalization or planned cardiac surgery
             within the next 3 months.

          -  Patients with spontaneous coronary artery dissection (SCAD), non-atherosclerotic
             coronary disease (NACAD), and Takotsubo cardiomyopathy are excluded from this study.

          -  Patients with contraindications to anticoagulation.

          -  Patients with a chronic skin disorder on the upper torso, or an allergy to medical
             tape or glue.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason G Andrade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason G Andrade, MD</last_name>
    <phone>604-875-4111</phone>
    <phone_ext>55069</phone_ext>
    <email>jason.andrade@vch.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher C Cheung, MD</last_name>
    <phone>604-875-4111</phone>
    <phone_ext>55069</phone_ext>
    <email>ccheung@alumni.ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Starovoytov, MD</last_name>
      <phone>604-875-5079</phone>
      <email>a.starovoytov@ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jackie Chow</last_name>
      <phone>604-877-3728</phone>
      <email>jackie.chow@vch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher C Cheung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jason Andrade</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>intensive monitoring</keyword>
  <keyword>oral anticoagulation</keyword>
  <keyword>hospitalization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

